https://www.pharmaradar360.com/article/uk-commits-to-pharma-ip-protection-in-swiss-trade-deal-4ee19ce62b080523Pharma Surgeen2026-07-16T16:12:35.000ZUK commits to pharma IP protection in Swiss trade dealhttps://www.pharmaradar360.com/article/pharmaceutical-company-cuts-energy-use-and-achieves-iso-compliance-with-compress-3dcf7713dd723262Pharma Surgeen2026-07-16T15:56:10.000ZPharmaceutical company cuts energy use and achieves ISO compliance with compressor and dryer upgradehttps://www.pharmaradar360.com/article/moneymasters-podcast-where-to-invest-now-in-ai-biotech-small-caps-gold-c7bea3639715272cPharma Surgeen2026-07-16T15:56:10.000ZMoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!https://www.pharmaradar360.com/article/banning-the-sale-of-high-caffeine-energy-drinks-to-children-2dd4d499a8a92623Pharma Surgeen2026-07-16T15:40:59.000ZBanning the sale of high-caffeine energy drinks to childrenhttps://www.pharmaradar360.com/article/promising-phase-2-and-3-influenza-therapies-what-pharmacists-should-know-6a9b0cec67f1c6f5Pharma Surgeen2026-07-16T15:37:27.000ZPromising Phase 2 and 3 Influenza Therapies: What Pharmacists Should Knowhttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662Pharma Surgeen2026-07-16T15:35:39.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/drofen-publishes-second-column-in-pharmaceutical-technology-launches-pen-injecto-cc10f29402c690a5Pharma Surgeen2026-07-16T15:33:00.000ZDROFEN Publishes Second Column in Pharmaceutical Technology, Launches Pen Injector Pre-Assembly Machinehttps://www.pharmaradar360.com/article/air-cooling-and-filtration-the-critical-utilities-behind-sterile-pharmaceutical-01cef57301d87e2aPharma Surgeen2026-07-16T15:31:09.000ZAir, cooling and filtration: The critical utilities behind sterile pharmaceutical productionhttps://www.pharmaradar360.com/article/physical-activity-guidelines-children-and-young-people-5-to-18-years-eb1510c88ccd3c58Pharma Surgeen2026-07-16T15:19:32.000ZPhysical activity guidelines: children and young people (5 to 18 years)https://www.pharmaradar360.com/article/physical-activity-guidelines-disabled-adults-e5b4126ee40a356bPharma Surgeen2026-07-16T15:19:26.000ZPhysical activity guidelines: disabled adultshttps://www.pharmaradar360.com/article/physical-activity-guidelines-pregnancy-and-after-childbirth-195d2b08fdc77ffbPharma Surgeen2026-07-16T15:19:18.000ZPhysical activity guidelines: pregnancy and after childbirthhttps://www.pharmaradar360.com/article/physical-activity-guidelines-early-years-under-5s-93de9a428b7393ffPharma Surgeen2026-07-16T15:19:12.000ZPhysical activity guidelines: early years (under 5s)https://www.pharmaradar360.com/article/banta-and-tooman-argue-strategic-questioning-improves-pharmaceutical-decision-ma-0a21e35c62e06ba2Pharma Surgeen2026-07-16T15:19:10.000ZBanta and Tooman Argue Strategic Questioning Improves Pharmaceutical Decision-Making and AI Integrationhttps://www.pharmaradar360.com/article/physical-activity-guidelines-adults-and-older-adults-24dfd3484d3377c6Pharma Surgeen2026-07-16T15:19:07.000ZPhysical activity guidelines: adults and older adultshttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-16T14:59:16.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/illumina-ordered-to-recall-products-after-german-patent-ruling-26ea60785aad2c2dPharma Surgeen2026-07-16T14:59:04.000ZIllumina ordered to recall products after German patent rulinghttps://www.pharmaradar360.com/article/merck-s-lipfendra-becomes-first-oral-cholesterol-pill-to-match-injectable-pcsk9-560d0d60e54792ebPharma Surgeen2026-07-16T14:49:34.000ZMerck’s Lipfendra Becomes First Oral Cholesterol Pill to Match Injectable PCSK9 Potencyhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-16T14:48:19.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/ofsted-and-care-quality-commission-shared-principles-for-local-government-reorga-0c60e32ff27e8b20Pharma Surgeen2026-07-16T14:47:58.000ZOfsted and Care Quality Commission: shared principles for local government reorganisationhttps://www.pharmaradar360.com/article/us-zinc-prices-hold-steady-in-early-july-as-pharmaceutical-demand-and-supply-cos-5584fb890ab6b4dfPharma Surgeen2026-07-16T14:44:38.000ZUS Zinc Prices Hold Steady in Early July as Pharmaceutical Demand and Supply Costs Support Markethttps://www.pharmaradar360.com/article/lilly-enters-psychedelic-realm-through-2-8bn-ataibeckley-takeover-04eba4124fe4b3cfPharma Surgeen2026-07-16T14:39:34.000ZLilly enters psychedelic realm through $2.8bn AtaiBeckley takeoverhttps://www.pharmaradar360.com/article/eli-lilly-lly-stock-dips-following-2-8b-ataibeckley-acquisition-for-depression-t-9014bf7a43d6c340Pharma Surgeen2026-07-16T14:20:40.000ZEli Lilly (LLY) Stock Dips Following $2.8B AtaiBeckley Acquisition for Depression Treatment Pipelinehttps://www.pharmaradar360.com/article/us-biotech-secures-150m-to-develop-potential-treatments-for-parkinson-s-d3f4907b60a56036Pharma Surgeen2026-07-16T14:04:03.000ZUS biotech secures $150M to develop potential treatments for Parkinson’shttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-earnings-expected-to-grow-what-to-know-ahead-of-dbba3f846b2f69dePharma Surgeen2026-07-16T14:00:13.000ZWest Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasehttps://www.pharmaradar360.com/article/lab-monkey-prices-soar-as-china-s-biotech-boom-fuels-windfall-for-breeders-ad9d898c55efbfc2Pharma Surgeen2026-07-16T14:00:06.000ZLab monkey prices soar as China’s biotech boom fuels windfall for breedershttps://www.pharmaradar360.com/article/how-lilly-s-ataibeckley-deal-accelerates-psychedelic-drug-commercialization-push-3caa77dc9d695042Pharma Surgeen2026-07-16T13:59:54.000ZHow Lilly's AtaiBeckley Deal Accelerates Psychedelic Drug Commercialization Pushhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-nkgen-biotech-inc-otc-nkgnw-37301e8376acdf7aPharma Surgeen2026-07-16T13:53:06.000ZPrice to earnings forward of NKGen Biotech Inc. – OTC:NKGNWhttps://www.pharmaradar360.com/article/briacell-bctx-expands-phase-3-study-with-new-clinical-site-345833b72b3b95fdPharma Surgeen2026-07-16T13:41:15.000ZBriaCell (BCTX) Expands Phase 3 Study with New Clinical Sitehttps://www.pharmaradar360.com/article/racing-takeda-innocare-reports-tyk2-inhibitor-win-in-phase-2-vitiligo-trial-d054c4619838ffa0Pharma Surgeen2026-07-16T13:36:42.000ZRacing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialhttps://www.pharmaradar360.com/article/care-workforce-pathway-for-adult-social-care-7c0f06f49dc43fcbPharma Surgeen2026-07-16T13:30:06.000ZCare workforce pathway for adult social carehttps://www.pharmaradar360.com/article/electronic-prescription-service-the-battle-for-nominations-ad58ea373822f6e4Pharma Surgeen2026-07-16T13:27:05.000ZElectronic prescription service: the battle for nominationshttps://www.pharmaradar360.com/article/jcvi-publishes-new-recommendation-to-government-on-adolescent-menb-vaccination-2c034385dd8837fbPharma Surgeen2026-07-16T13:25:31.000ZJCVI publishes new recommendation to Government on adolescent MenB vaccinationhttps://www.pharmaradar360.com/article/merck-dives-into-cholesterol-with-first-fda-approval-for-oral-pcsk9-inhibitor-b9235d486fcd89b9Pharma Surgeen2026-07-16T13:22:23.000ZMerck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-newland-pharmaceutical-co-ltd-class-a-szse-3-efb16c2b0d9d8816Pharma Surgeen2026-07-16T13:20:38.000ZEnterprise value to EBIT forward of Newland Pharmaceutical Co., Ltd. Class A – SZSE:301277https://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-kalshi-bets-on-clinical-trials-a-merck-choleste-a46031c4fc58af05Pharma Surgeen2026-07-16T13:15:51.000ZPharmalittle: We're reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and morehttps://www.pharmaradar360.com/article/kalshi-launches-biotech-prediction-markets-pilot-program-c9237e46fc1efbaePharma Surgeen2026-07-16T13:15:43.000ZKalshi launches biotech prediction markets pilot programhttps://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-07-16T13:06:54.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/fda-approves-merck-s-oral-pcsk9-drug-a-first-da9c830b9ab8cf4fPharma Surgeen2026-07-16T13:06:07.000ZFDA approves Merck’s oral PCSK9 drug, a firsthttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-16T13:00:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-16T13:00:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-16T13:00:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-16T13:00:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-16T13:00:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-16T13:00:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-07-16T13:00:02.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69Pharma Surgeen2026-07-16T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/jcvi-statement-on-meningococcal-b-vaccination-in-older-children-and-young-adults-26c1361f3a11f5e2Pharma Surgeen2026-07-16T13:00:02.000ZJCVI statement on meningococcal B vaccination in older children and young adults, 16 July 2026https://www.pharmaradar360.com/article/covid-19-vaccination-in-autumn-2027-jcvi-advice-14ee41f243122ef5Pharma Surgeen2026-07-16T13:00:02.000ZCOVID-19 vaccination in autumn 2027: JCVI advicehttps://www.pharmaradar360.com/article/plans-for-fair-pay-agreements-in-adult-social-care-easy-read-8df471110bb66761Pharma Surgeen2026-07-16T13:00:02.000ZPlans for fair pay agreements in adult social care (easy read)https://www.pharmaradar360.com/article/fair-pay-agreement-process-in-adult-social-care-15dd92c98eb8b8ffPharma Surgeen2026-07-16T13:00:02.000ZFair pay agreement process in adult social carehttps://www.pharmaradar360.com/article/all-cause-mortality-surveillance-8e78ac3be4ec1572Pharma Surgeen2026-07-16T13:00:02.000ZAll-cause mortality surveillancehttps://www.pharmaradar360.com/article/flu-vaccines-2027-to-2028-jcvi-advice-16-july-2026-c0a1820d73e3a4a7Pharma Surgeen2026-07-16T13:00:00.000ZFlu vaccines 2027 to 2028: JCVI advice, 16 July 2026https://www.pharmaradar360.com/article/medtronic-completes-acquisition-of-spr-expanding-patient-access-to-minimally-inv-09db69210d9d2676Pharma Surgeen2026-07-16T13:00:00.000ZMedtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute painhttps://www.pharmaradar360.com/article/breaking-world-s-largest-pharmaceutical-company-eli-lilly-acquires-5-meo-dmt-dev-caeb382d220c4672Pharma Surgeen2026-07-16T12:41:35.000ZBreaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billionhttps://www.pharmaradar360.com/article/eli-lilly-confirms-rumors-makes-a-bid-for-ataibeckley-0dcedc44e4f055f6Pharma Surgeen2026-07-16T12:30:25.000ZEli Lilly confirms rumors: Makes a bid for AtaiBeckleyhttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-94c6c1735397020aPharma Surgeen2026-07-16T12:26:24.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metas-4e9827b67b758c59Pharma Surgeen2026-07-16T12:23:34.000ZBriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancerhttps://www.pharmaradar360.com/article/aspen-reaches-more-than-920-000-beneficiaries-through-mandela-day-cffe06c33b5b990aPharma Surgeen2026-07-16T12:22:37.000ZAspen reaches more than 920 000 beneficiaries through Mandela Dayhttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-in-up-to-3-8-billion-mental-health-deal-e5c7bad82c425134Pharma Surgeen2026-07-16T12:14:09.000ZLilly to Acquire AtaiBeckley in Up to $3.8 Billion Mental Health Dealhttps://www.pharmaradar360.com/article/kalshi-expands-into-biotech-with-clinical-trial-wagers-by-investing-com-1b7b3694357e7ed4Pharma Surgeen2026-07-16T12:11:37.000ZKalshi expands into biotech with clinical trial wagers By Investing.comhttps://www.pharmaradar360.com/article/kalshi-expands-into-biotech-with-clinical-trial-wagers-84e8ad47f5b4528dPharma Surgeen2026-07-16T12:10:08.000ZKalshi expands into biotech with clinical trial wagershttps://www.pharmaradar360.com/article/pharma-pulse-cvs-credits-trumprx-to-deductibles-germany-hikes-drug-rebates-fd4ce7d829603cd0Pharma Surgeen2026-07-16T12:09:49.000ZPharma Pulse: CVS Credits TrumpRx to Deductibles, Germany Hikes Drug Rebateshttps://www.pharmaradar360.com/article/la-aemps-informa-de-un-posible-fallo-en-la-aplicacion-minimed-go-para-la-diabete-539fe29529fdc65bPharma Surgeen2026-07-16T12:09:32.000ZLa AEMPS informa de un posible fallo en la aplicación MiniMed Go para la diabetes que afecta al funcionamiento de las alertas nocturnashttps://www.pharmaradar360.com/article/kalshi-comes-for-biopharma-with-prediction-markets-for-clinical-trials-and-fda-a-013c3406002f76c5Pharma Surgeen2026-07-16T12:01:07.000ZKalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalshttps://www.pharmaradar360.com/article/life-changing-ms-drugs-to-stay-on-the-pbs-so-why-are-others-under-threat-and-how-c896dd1fcb9b1a57Pharma Surgeen2026-07-16T12:01:00.000ZLife-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?https://www.pharmaradar360.com/article/strykeflow-ps-and-ahto-ce836196a5199121Pharma Surgeen2026-07-16T12:00:00.000ZStrykeFlow PS and AHTOhttps://www.pharmaradar360.com/article/solartm-gi-dae44a3754bab86cPharma Surgeen2026-07-16T12:00:00.000ZSolar™ GIhttps://www.pharmaradar360.com/article/sema-3-b7832afdb64b9c9fPharma Surgeen2026-07-16T12:00:00.000ZSEMA 3https://www.pharmaradar360.com/article/kalshi-will-offer-sports-style-betting-on-drug-trial-results-204099a71093e481Pharma Surgeen2026-07-16T12:00:00.000ZKalshi Will Offer Sports-Style Betting on Drug Trial Resultshttps://www.pharmaradar360.com/article/grifols-trial-could-expand-treatment-options-for-60-000-patients-d3a4b6925cf2cd6aPharma Surgeen2026-07-16T12:00:00.000ZGrifols Trial Could Expand Treatment Options for 60,000 Patientshttps://www.pharmaradar360.com/article/tavneos-avacopan-07a6eea404db70c3Pharma Surgeen2026-07-16T11:45:32.000ZTavneos (avacopan): Απευθείας επικοινωνία προς επαγγελματίες υγείαςhttps://www.pharmaradar360.com/article/vegan-pdrn-is-reshaping-regenerative-skincare-as-biotech-alternatives-gain-momen-d80c7a4013b8b693Pharma Surgeen2026-07-16T11:37:24.000ZVegan PDRN Is Reshaping Regenerative Skincare as Biotech Alternatives Gain Momentumhttps://www.pharmaradar360.com/article/eli-lilly-to-acquire-psychedelics-focused-biotech-ataibeckley-ea922cb5f0ed02aePharma Surgeen2026-07-16T11:35:33.000ZEli Lilly to acquire psychedelics-focused biotech AtaiBeckleyhttps://www.pharmaradar360.com/article/lilly-buys-ataibeckley-for-2-8b-upfront-to-challenge-j-j-for-psychedelic-mental-582006a5d22f1f36Pharma Surgeen2026-07-16T11:32:42.000ZLilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health markethttps://www.pharmaradar360.com/article/sandoz-reshapes-leadership-to-capitalise-on-biosimilar-golden-decade-175ac7c0e324e450Pharma Surgeen2026-07-16T11:31:12.000ZSandoz reshapes leadership to capitalise on biosimilar golden decadehttps://www.pharmaradar360.com/article/nature-medicine-features-briacell-trial-among-11-that-will-shape-medicine-64194b54bb969718Pharma Surgeen2026-07-16T11:30:00.000ZNature Medicine Features BriaCell Trial Among 11 That Will Shape Medicinehttps://www.pharmaradar360.com/article/russian-reference-standards-centre-expands-into-pharmaceutical-wholesale-and-sto-a5defe6d27895847Pharma Surgeen2026-07-16T11:19:40.000ZRussian reference standards centre expands into pharmaceutical wholesale and storagehttps://www.pharmaradar360.com/article/eli-lilly-buys-psychedelic-biotech-backed-by-peter-thiel-ada260ea5506af7cPharma Surgeen2026-07-16T11:13:25.000ZEli Lilly buys psychedelic biotech backed by Peter Thielhttps://www.pharmaradar360.com/article/single-use-sterile-bioprocessing-tools-36e8ca0c44048cc5Pharma Surgeen2026-07-16T11:09:47.000ZSingle-Use Sterile Bioprocessing Toolshttps://www.pharmaradar360.com/article/single-use-sterile-bioprocessing-tools-2e820dff4d0ef8b6Pharma Surgeen2026-07-16T11:09:46.000ZSingle-Use Sterile Bioprocessing Toolshttps://www.pharmaradar360.com/article/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-ac8232b26f2a9208Pharma Surgeen2026-07-16T11:05:00.000ZRelmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026https://www.pharmaradar360.com/article/european-biotech-act-advances-biotechnology-innovation-5a48e492d66c07caPharma Surgeen2026-07-16T11:03:07.000ZEuropean Biotech Act Advances Biotechnology Innovationhttps://www.pharmaradar360.com/article/fedex-life-sciences-launches-to-support-pharmaceutical-logistics-eb60a6b5c3d54a1cPharma Surgeen2026-07-16T11:00:11.000ZFedEx Life Sciences launches to support pharmaceutical logisticshttps://www.pharmaradar360.com/article/moderna-trial-tests-cancer-therapy-encoding-seven-antigens-bbd9868fc112b037Pharma Surgeen2026-07-16T11:00:00.000ZModerna Trial Tests Cancer Therapy Encoding Seven Antigenshttps://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-16T10:55:41.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/eli-lilly-to-buy-psychedelics-maker-ataibeckley-for-2-8-billion-as-experimental-c83ccd6c6c9de6e5Pharma Surgeen2026-07-16T10:45:53.000ZEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionhttps://www.pharmaradar360.com/article/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-f513ffd9e62e44adPharma Surgeen2026-07-16T10:45:00.000ZMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemiahttps://www.pharmaradar360.com/article/ataibeckley-s-bpl-003-shows-months-of-effects-after-2-hour-visits-c7ddce453dd42815Pharma Surgeen2026-07-16T10:45:00.000ZAtaiBeckley’s BPL-003 Shows Months of Effects After 2-Hour Visitshttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-to-advance-therapies-for-treatment-resistant-depres-52ec112919ea8e7ePharma Surgeen2026-07-16T10:45:00.000ZLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionshttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-to-advance-therapies-for-treatment-resistant-depres-f3af133918fbe32cPharma Surgeen2026-07-16T10:45:00.000ZLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionshttps://www.pharmaradar360.com/article/1-2026-4f0a4b02170c7516Pharma Surgeen2026-07-16T10:38:07.000ZΜΗΣΥΦΑ 1ου Τριμήνου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/amylyx-nears-pivotal-endocrine-drug-study-readout-ff39615c409c8942Pharma Surgeen2026-07-16T10:35:33.000ZAmylyx nears pivotal endocrine drug study readouthttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-del-mercado-de-determinadas-canulas-guedel-de-un-01a6419ed76e2626Pharma Surgeen2026-07-16T10:33:45.000ZLa AEMPS informa de la retirada del mercado de determinadas cánulas Guedel de una sola piezahttps://www.pharmaradar360.com/article/datroway-ec8ad2f1de7fa374Pharma Surgeen2026-07-16T10:33:28.000ZDatrowayhttps://www.pharmaradar360.com/article/biomarin-bmrn-wins-fda-review-for-voxzogo-full-approval-in-achondroplasia-40dbb7257304ea50Pharma Surgeen2026-07-16T10:31:37.000ZBioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasiahttps://www.pharmaradar360.com/article/italy-s-angelini-pharma-completes-4-1-billion-state-backed-takeover-of-catalyst-01b453d29b162daePharma Surgeen2026-07-16T10:20:23.000ZItaly's Angelini Pharma completes $4.1 billion state-backed takeover of Catalysthttps://www.pharmaradar360.com/article/biomarkers-in-nephrology-research-from-exploratory-to-decision-making-tools-2290c940259f3fc1Pharma Surgeen2026-07-16T10:17:07.000ZBiomarkers in Nephrology Research: From Exploratory to Decision-Making Toolshttps://www.pharmaradar360.com/article/annex-1-sterilisation-why-pharma-packaging-strategy-is-changing-d0874f189c71fd8bPharma Surgeen2026-07-16T10:17:07.000ZAnnex 1 sterilisation: Why pharma packaging strategy is changinghttps://www.pharmaradar360.com/article/malaria-prevention-guidelines-for-travellers-from-the-uk-2026-bfdb8582fd85690ePharma Surgeen2026-07-16T10:08:15.000ZMalaria prevention guidelines for travellers from the UK 2026https://www.pharmaradar360.com/article/zymeworks-to-report-second-quarter-2026-financial-results-on-august-6-2026-68d6d4f3343f072cPharma Surgeen2026-07-16T10:04:10.000ZZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026https://www.pharmaradar360.com/article/biomed-industries-presents-promising-phase-2-3-clinical-results-of-na-921-for-re-6af9732cd4b928fbPharma Surgeen2026-07-16T10:00:00.000ZBiomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026https://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-asthma-therapy-0b293e653e6af0a5Pharma Surgeen2026-07-16T09:59:04.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyhttps://www.pharmaradar360.com/article/vogenx-c38a702ec62820c8Pharma Surgeen2026-07-16T09:58:43.000ZVogenxhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-16T09:50:26.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/j-j-tops-25-billion-quarter-lifts-2026-outlook-bece073262a14099Pharma Surgeen2026-07-16T09:47:32.000ZJ&J tops $25 billion quarter, lifts 2026 outlookhttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-16T09:44:51.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-seis-lotes-del-medicamento-veterinario-moduli-bcd4952599605e76Pharma Surgeen2026-07-16T09:41:36.000ZLa AEMPS informa de la retirada de seis lotes del medicamento veterinario Modulis 100mg/ml solución oral para perroshttps://www.pharmaradar360.com/article/modulis-100-mg-ml-solucion-oral-para-perros-no-3178-esp-229f003566a30325Pharma Surgeen2026-07-16T09:40:34.000ZMODULIS 100 MG/ML SOLUCION ORAL PARA PERROS (Nº 3178 ESP)https://www.pharmaradar360.com/article/bayer-adds-a-spine-to-modularity-for-scale-without-disruption-7d6fd16e3046de5fPharma Surgeen2026-07-16T09:24:30.000ZBayer Adds A Spine To Modularity For Scale Without Disruptionhttps://www.pharmaradar360.com/article/nihr-sphr-transdisciplinary-fellowships-in-public-health-research-2026-1f2621f6ecd2812aPharma Surgeen2026-07-16T09:23:29.000ZNIHR SPHR Transdisciplinary Fellowships in public health research 2026https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-shows-high-growth-momentum-with-perfect-minervini-tr-3623183038eb9a0bPharma Surgeen2026-07-16T09:20:28.000ZKrystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setuphttps://www.pharmaradar360.com/article/vogenx-joins-the-ipo-queue-to-fund-phase-2-stage-metabolic-drug-3ea5708412500b7dPharma Surgeen2026-07-16T09:19:05.000ZVogenx joins the IPO queue to fund phase 2-stage metabolic drughttps://www.pharmaradar360.com/article/global-penny-stocks-guizhou-yibai-pharmaceutical-and-2-more-to-watch-a1ee61041a90e090Pharma Surgeen2026-07-16T09:15:54.000ZGlobal Penny Stocks: Guizhou Yibai Pharmaceutical And 2 More To Watchhttps://www.pharmaradar360.com/article/top-five-global-pharma-signs-deal-to-test-kangstem-s-hair-follicle-organoids-for-5ffaa0e135f070f4Pharma Surgeen2026-07-16T09:03:49.000ZTop-five global pharma signs deal to test Kangstem’s hair follicle organoids for hair-loss drugshttps://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-asthma-therapy-53613018630f4883Pharma Surgeen2026-07-16T09:00:28.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyhttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-press-release-pursuant-to-article-36-of-the-is-0643304fbc750a67Pharma Surgeen2026-07-16T08:54:00.000ZOn behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 36 of the Issuers’ Regulationhttps://www.pharmaradar360.com/article/small-molecules-still-do-the-heavy-lifting-in-drug-development-029381492555c8e2Pharma Surgeen2026-07-16T08:49:03.000ZSmall molecules still do the heavy lifting in drug developmenthttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-07-16T08:41:31.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-s-b46c9c5c900a9ce9Pharma Surgeen2026-07-16T08:35:04.000ZKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/geodis-strengthens-pharmaceutical-logistics-capabilities-in-poland-187bbe9d9d82c461Pharma Surgeen2026-07-16T08:32:41.000ZGEODIS strengthens pharmaceutical logistics capabilities in Polandhttps://www.pharmaradar360.com/article/framework-agreements-between-the-department-of-health-and-social-care-and-its-ar-10908850a6438af4Pharma Surgeen2026-07-16T08:30:06.000ZFramework agreements between the Department of Health and Social Care and its arm’s length bodieshttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-16T08:30:05.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/bloodborne-viruses-managing-risk-in-bomb-blast-victims-adf8b25c8152aab9Pharma Surgeen2026-07-16T08:30:01.000ZBloodborne viruses: managing risk in bomb blast victimshttps://www.pharmaradar360.com/article/framework-agreement-between-dhsc-and-the-human-fertilisation-and-embryology-auth-2a0fe3c241cea627Pharma Surgeen2026-07-16T08:30:00.000ZFramework agreement between DHSC and the Human Fertilisation and Embryology Authority: 2026 to 2029https://www.pharmaradar360.com/article/preparing-for-the-pharma-fraud-enforcement-surge-e4d2970b84515fcePharma Surgeen2026-07-16T08:30:00.000ZPreparing for the pharma fraud enforcement surgehttps://www.pharmaradar360.com/article/testing-the-hypothesis-a-focused-pilot-for-ai-in-healthcare-99ed98de69be6a2dPharma Surgeen2026-07-16T08:17:35.000ZTesting the hypothesis: a focused pilot for AI in healthcarehttps://www.pharmaradar360.com/article/care-workers-to-be-represented-in-fair-pay-agreements-f15c5f1f347b1e65Pharma Surgeen2026-07-16T08:15:00.000ZCare workers to be represented in fair pay agreementshttps://www.pharmaradar360.com/article/can-cah-sustain-growth-on-booming-pharmaceutical-specialty-segment-9dce455c9008daf3Pharma Surgeen2026-07-16T08:09:04.000ZCan CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?https://www.pharmaradar360.com/article/us-biotech-biogen-hires-spur-therapeutics-ceo-as-next-legal-chief-51a1cae8dcf9b693Pharma Surgeen2026-07-16T07:56:00.000ZUS biotech Biogen hires Spur Therapeutics CEO as next legal chiefhttps://www.pharmaradar360.com/article/3-high-growth-mining-and-biotech-stocks-with-healthy-balance-sheets-11ac602cd64257cdPharma Surgeen2026-07-16T07:38:12.000Z3 High Growth Mining And Biotech Stocks With Healthy Balance Sheetshttps://www.pharmaradar360.com/article/kosdaq-listed-biotech-alteogen-slides-amid-rival-technology-concerns-dda02d7b60b4008ePharma Surgeen2026-07-16T06:53:41.000ZKOSDAQ-listed biotech Alteogen slides amid rival technology concernshttps://www.pharmaradar360.com/article/empowering-fine-chemicals-through-technological-innovation-wisdom-pharmaceutical-78003a34b14d2cf2Pharma Surgeen2026-07-16T06:43:49.000ZEmpowering Fine Chemicals through Technological Innovation–Wisdom Pharmaceutical Connects Global Pharmaceutical and Agrochemical Markets - ChemNethttps://www.pharmaradar360.com/article/niagen-bioscience-inc-nage-discusses-strategic-expansion-into-pharmaceutical-dev-d3a284e98c609ab3Pharma Surgeen2026-07-16T06:30:45.000ZNiagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program - Slideshow (NASDAQ:NAGE) 2026-07-16https://www.pharmaradar360.com/article/89478ca09cf0bcc8Pharma Surgeen2026-07-16T06:06:08.000ZΔήλωση Αποθεμάτων Φαρμάκων Ανθρώπινης Χρήσηςhttps://www.pharmaradar360.com/article/usc-alfred-e-mann-school-of-pharmacy-and-pharmaceutical-sciences-787f3cac2ac46793Pharma Surgeen2026-07-16T05:58:11.000ZUSC Alfred E. Mann School of Pharmacy and Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/j-j-raises-fy26-outlook-following-positive-q2-bf5ed898f58b39e8Pharma Surgeen2026-07-16T04:29:51.000ZJ&J raises FY26 outlook following positive Q2https://www.pharmaradar360.com/article/biotech-company-protransit-introduces-free-radical-fighting-skincare-brand-echel-28cf762ce33f5b4ePharma Surgeen2026-07-16T04:01:16.000ZBiotech Company ProTransit Introduces Free Radical-Fighting Skincare Brand Échelonhttps://www.pharmaradar360.com/article/convenience-kit-recall-b-braun-medical-inc-removes-spinal-anesthesia-kits-contai-09128b3399f3dad8Pharma Surgeen2026-07-16T04:00:00.000ZConvenience Kit Recall: B. Braun Medical, Inc. Removes Spinal Anesthesia Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USPhttps://www.pharmaradar360.com/article/convenience-kit-correction-arrow-international-issues-correction-for-convenience-8342295f160476fePharma Surgeen2026-07-16T04:00:00.000ZConvenience Kit Correction: Arrow International Issues Correction for Convenience Kits Containing Recalled Huons Lidocaine and Bupivacaine and Salinehttps://www.pharmaradar360.com/article/ketan-agarwal-murder-case-fda-seizes-food-products-worth-8-14-lakh-from-siya-goy-e03c5e403657cc14Pharma Surgeen2026-07-16T03:17:53.000ZKetan Agarwal Murder Case: FDA Seizes Food Products Worth ₹8.14 Lakh From Siya Goyals Fathers Pune Shophttps://www.pharmaradar360.com/article/biotech-venture-funding-roars-back-272491de7fff8b98Pharma Surgeen2026-07-16T03:17:28.000ZBiotech Venture Funding Roars Backhttps://www.pharmaradar360.com/article/chinese-fund-managers-increase-biotech-holdings-in-hong-kong-amid-attractive-val-2a34a2cb093c3814Pharma Surgeen2026-07-16T03:11:00.000ZChinese Fund Managers Increase Biotech Holdings in Hong Kong Amid Attractive Valuations - News and Statisticshttps://www.pharmaradar360.com/article/mainland-funds-boost-stakes-in-hong-kong-listed-biotech-amid-value-dislocation-1f46de8fc253cb96Pharma Surgeen2026-07-16T03:03:20.000ZMainland funds boost stakes in Hong Kong-listed biotech amid value dislocationhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-vorzzz-cef91b05fad6e791Pharma Surgeen2026-07-16T03:00:00.000Z[SHINSA]English Translation of Review Report: Vorzzzhttps://www.pharmaradar360.com/article/st-pharm-s-hiv-drug-candidate-shows-97-5-viral-load-reduction-in-phase-2a-trial-77f4cdd99f2580e9Pharma Surgeen2026-07-16T02:46:00.000ZST Pharm's HIV Drug Candidate Shows 97.5% Viral Load Reduction in Phase 2a Trial, Boosting Licensing Prospectshttps://www.pharmaradar360.com/article/loss-making-noile-immune-biotech-inc-tse-4893-expected-to-breakeven-in-the-mediu-c5d0de1aa5a6359ePharma Surgeen2026-07-16T02:20:28.000ZLoss-Making Noile-Immune Biotech Inc. (TSE:4893) Expected To Breakeven In The Medium-Termhttps://www.pharmaradar360.com/article/the-next-rare-earths-why-us-fears-another-chinese-manufacturing-advantage-9f62815539d161e5Pharma Surgeen2026-07-16T01:59:20.000ZThe next rare earths? Why US fears another Chinese manufacturing advantagehttps://www.pharmaradar360.com/article/connecticut-receiving-388k-from-multi-state-settlement-with-glenmark-pharmaceuti-13f13fec529d1569Pharma Surgeen2026-07-16T01:49:00.000ZConnecticut receiving $388K from multi-state settlement with Glenmark pharmaceutical companyhttps://www.pharmaradar360.com/article/senate-bill-seeks-to-curb-us-reliance-on-china-in-drug-industry-a8c57f2d4f1bcca4Pharma Surgeen2026-07-16T00:38:29.000ZSenate bill seeks to curb US reliance on China in drug industryhttps://www.pharmaradar360.com/article/braveheart-bio-attovia-join-growing-pipeline-of-biotech-ipos-07a203c2bed21675Pharma Surgeen2026-07-16T00:36:00.000ZBraveheart Bio, Attovia Join Growing Pipeline Of Biotech IPOshttps://www.pharmaradar360.com/article/mfn-drug-pricing-what-pharmaceutical-manufacturers-need-to-know-about-their-inte-1eb1952c48da10eaPharma Surgeen2026-07-16T00:29:44.000ZMFN Drug Pricing: What Pharmaceutical Manufacturers Need To Know About Their International Agreements (Video)https://www.pharmaradar360.com/article/algorae-names-nasdaq-pharmaceutical-chairman-to-strengthen-board-d41dee70cc791708Pharma Surgeen2026-07-16T00:11:22.000ZAlgorae names Nasdaq pharmaceutical chairman to strengthen boardhttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-75e795aa081cedf5Pharma Surgeen2026-07-16T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/otsuka-foods-to-launch-new-my-size-plus-support-w-double-delivering-nutritional-abaad7f259228c45Pharma Surgeen2026-07-16T00:00:00.000ZOtsuka Foods to Launch New “My Size Plus Support W (Double)” Delivering Nutritional Support and Salt Control in One Product Available at Dispensing Pharmacies and Select Drugstores across Japan on July 31, 2026https://www.pharmaradar360.com/article/thousands-eligible-for-new-chronic-heart-failure-treatment-following-nice-recomm-6eaada26f019210ePharma Surgeen2026-07-16T00:00:00.000ZThousands eligible for new chronic heart failure treatment following NICE recommendationhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-16T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-f79a5f4ea34ff840Pharma Surgeen2026-07-16T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-1e75f37325500bc8Pharma Surgeen2026-07-16T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-f4a0aeec504b078dPharma Surgeen2026-07-16T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1c6f976fc036e64ePharma Surgeen2026-07-16T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-0eae370776c342ddPharma Surgeen2026-07-16T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-033a4af77ac7d1dfPharma Surgeen2026-07-16T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-6703234e0fba5735Pharma Surgeen2026-07-16T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-0c164e42823e647fPharma Surgeen2026-07-16T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-4751526d33ccdeacPharma Surgeen2026-07-16T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b67e4602292943c5Pharma Surgeen2026-07-16T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fd6c7213fbdeaeacPharma Surgeen2026-07-16T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-8b38c495a81bc2a0Pharma Surgeen2026-07-16T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-db4afeda2ce1c082Pharma Surgeen2026-07-16T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-7501e8a73c404666Pharma Surgeen2026-07-16T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/order-under-sections-362-and-365-of-the-public-health-service-act-continuing-the-51ddf79b7eb02fb9Pharma Surgeen2026-07-16T00:00:00.000ZOrder Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Existshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-d74fd2dc7c11ebf2Pharma Surgeen2026-07-16T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/medicaid-and-children-s-health-insurance-program-chip-generic-information-collec-c4441bb30ddf7591Pharma Surgeen2026-07-16T00:00:00.000ZMedicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/request-for-information-clinical-laboratory-improvement-amendments-of-1988-clia-03d560f0394d578bPharma Surgeen2026-07-16T00:00:00.000ZRequest for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulationshttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-method-of-manufacturing-papillo-5ae4948e432e3383Pharma Surgeen2026-07-16T00:00:00.000ZGovernment Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)https://www.pharmaradar360.com/article/government-owned-invention-available-for-license-selective-expansion-of-engineer-c88ae775347c6da1Pharma Surgeen2026-07-16T00:00:00.000ZGovernment Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapyhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-chimeric-antigen-receptors-targ-c73e5bc8759fd75dPharma Surgeen2026-07-16T00:00:00.000ZGovernment Owned Invention Available for License: Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptorhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-fddb2f2a22cd969fPharma Surgeen2026-07-16T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-cy-2027-payment-policies-under-the-physician-fee-64f1dc34c8c5f8b2Pharma Surgeen2026-07-16T00:00:00.000ZMedicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Programhttps://www.pharmaradar360.com/article/patient-safety-organizations-expired-listing-for-the-informed-patient-safety-org-1378b1b2a0cce240Pharma Surgeen2026-07-16T00:00:00.000ZPatient Safety Organizations: Expired Listing for the Informed Patient Safety Organization (IPSO)https://www.pharmaradar360.com/article/meeting-of-the-advisory-board-on-radiation-and-worker-health-national-institute-3ec14233dc1d3649Pharma Surgeen2026-07-16T00:00:00.000ZMeeting of the Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Healthhttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-child-and-family-services-52f2f7fe2a147e44Pharma Surgeen2026-07-16T00:00:00.000ZSubmission for Office of Management and Budget Review; Child and Family Services Plan, Annual Progress and Services Report, and Annual Budget Expenses Request and Estimated Expenditures (Child and Family Services-101)https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-catalent-greenville-inc-2eaf5ba948afbf4fPharma Surgeen2026-07-16T00:00:00.000ZImporter of Controlled Substances Application: Catalent Greenville, Inc.https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-unither-manufacturing-llc-572a5054f869d1d0Pharma Surgeen2026-07-16T00:00:00.000ZImporter of Controlled Substances Application: Unither Manufacturing LLChttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-ampac-fine-chemicals-llc-134bdf63d8528e1aPharma Surgeen2026-07-16T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals LLChttps://www.pharmaradar360.com/article/process-for-fda-data-requests-to-inform-certain-over-the-counter-monograph-drug-3d10ecfff0fa44e6Pharma Surgeen2026-07-16T00:00:00.000ZProcess for FDA Data Requests To Inform Certain Over-the-Counter Monograph Drug Activities; Procedurehttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-catalent-cts-llc-3f06039010cf1722Pharma Surgeen2026-07-16T00:00:00.000ZImporter of Controlled Substances Application: Catalent CTS, LLChttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-evaluation-of-the-next-gen-19cd3312fdbe0717Pharma Surgeen2026-07-16T00:00:00.000ZSubmission for Office of Management and Budget Review; Evaluation of the Next Generation Child Support Employment Services Demonstrationhttps://www.pharmaradar360.com/article/perioperative-hypothermia-in-medium-and-large-volume-plastic-surgery-clinical-an-fe9a9c7841bf73f8Pharma Surgeen2026-07-16T00:00:00.000ZPerioperative Hypothermia in Medium- and Large-Volume Plastic Surgery: Clinical and Surgical Implications and Practical Prevention Strategieshttps://www.pharmaradar360.com/article/the-bio-physiological-impact-of-nidra-vega-dharana-suppression-of-the-sleep-urge-50569df66cd23e77Pharma Surgeen2026-07-16T00:00:00.000ZThe Bio-Physiological Impact of Nidra Vega Dharana (Suppression of the Sleep Urge): An Ayurvedic and Modern Clinical Reviewhttps://www.pharmaradar360.com/article/does-hypothyroidism-influence-left-bundle-branch-area-pacing-outcomes-mechanisti-38ff762ccb8b415aPharma Surgeen2026-07-16T00:00:00.000ZDoes Hypothyroidism Influence Left Bundle Branch Area Pacing Outcomes? Mechanistic Insights and Clinical Implicationshttps://www.pharmaradar360.com/article/clinical-and-health-system-factors-associated-with-antiretroviral-therapy-adhere-8197c2bb70004630Pharma Surgeen2026-07-16T00:00:00.000ZClinical and health system factors associated with antiretroviral therapy adherence among people living with HIV and AIDS: cross-sectional survey insights from three ART facilities in Tamale, Ghanahttps://www.pharmaradar360.com/article/natural-products-in-modern-drug-discovery-advances-challenges-and-emerging-techn-ab4f3a55f2fb173cPharma Surgeen2026-07-16T00:00:00.000ZNatural Products in Modern Drug Discovery: Advances, Challenges and Emerging Technologieshttps://www.pharmaradar360.com/article/combined-aerobic-resistance-training-and-taurine-supplementation-reduce-asprosin-fa3ca0a96804f127Pharma Surgeen2026-07-16T00:00:00.000ZCombined Aerobic–Resistance Training and Taurine Supplementation Reduce Asprosin and Elevate Spexin in Men with Obesity: A 12-Week Supplement-Blinded, Randomized Controlled Trialhttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-of-myval-vs-acurate-neo-valves-in-tavr-a-single-8230bbd9710fe587Pharma Surgeen2026-07-16T00:00:00.000ZComparison of Clinical Outcomes of Myval vs. Acurate Neo Valves in TAVR: A Single-Center Experiencehttps://www.pharmaradar360.com/article/preoperative-urodynamics-in-pelvic-organ-prolapse-to-identify-postoperative-inco-880fd1e54052d9daPharma Surgeen2026-07-16T00:00:00.000ZPreoperative Urodynamics in Pelvic Organ Prolapse to Identify Postoperative Incontinencehttps://www.pharmaradar360.com/article/transcatheter-versus-mechanical-and-bioprosthetic-surgical-aortic-valve-replacem-5694977df28d22d0Pharma Surgeen2026-07-16T00:00:00.000ZTranscatheter Versus Mechanical and Bioprosthetic Surgical Aortic Valve Replacement in Retrospective Patient Cohorts with Aortic Stenosis &lt;75 Yearshttps://www.pharmaradar360.com/article/association-of-hyperuricemia-with-the-onset-and-progression-of-type-2-diabetic-r-15eae375077e3199Pharma Surgeen2026-07-16T00:00:00.000ZAssociation of Hyperuricemia with the Onset and Progression of Type 2 Diabetic Retinopathyhttps://www.pharmaradar360.com/article/comparison-of-efficacy-and-safety-of-denosumab-with-eldecalcitol-or-native-vitam-11916a4cba406205Pharma Surgeen2026-07-16T00:00:00.000ZComparison of Efficacy and Safety of Denosumab with Eldecalcitol or Native Vitamin D in Postmenopausal Chinese Women with Osteoporosis (ESCORT): A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/examining-clinical-educators-readiness-for-artificial-intelligence-in-medical-ed-272381f7ac17f664Pharma Surgeen2026-07-16T00:00:00.000ZExamining Clinical Educators’ Readiness for Artificial Intelligence in Medical Education: An Exploratory Qualitative Studyhttps://www.pharmaradar360.com/article/n-acetylcysteine-in-endometriosis-a-systematic-review-of-biological-rationale-an-29fd91f09f71ea68Pharma Surgeen2026-07-16T00:00:00.000ZN-Acetylcysteine in Endometriosis: A Systematic Review of Biological Rationale and Clinical Evidencehttps://www.pharmaradar360.com/article/from-online-collaboration-to-clinical-insight-identifying-heterotopic-ossificati-5f394ef10c27d83dPharma Surgeen2026-07-16T00:00:00.000ZFrom online collaboration to clinical insight: identifying heterotopic ossification through a global hernia surgery networkhttps://www.pharmaradar360.com/article/clinical-characteristics-and-associated-factors-of-airway-allergic-diseases-amon-7f1e8f2c1e4df1c5Pharma Surgeen2026-07-16T00:00:00.000ZClinical characteristics and associated factors of airway allergic diseases among children: a cross-sectional study in a district of Beijinghttps://www.pharmaradar360.com/article/assessing-the-relationship-between-body-mass-index-and-influenza-like-illness-ri-9d598d44327cb533Pharma Surgeen2026-07-16T00:00:00.000ZAssessing the relationship between body mass index and influenza-like illness risk and symptom severity among military health system beneficiaries vaccinated against influenza: a pooled prospective cohort study from a randomized trialhttps://www.pharmaradar360.com/article/harmonizing-mind-acupuncture-combined-with-nicotine-replacement-therapy-for-toba-1016f63c2054b9c5Pharma Surgeen2026-07-16T00:00:00.000ZHarmonizing mind acupuncture combined with nicotine replacement therapy for tobacco use disorder: a protocol for a pragmatic randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-outcomes-of-atrial-tachyarrhythmia-hospitalizations-with-and-without-pr-bfbca6e075f4111bPharma Surgeen2026-07-16T00:00:00.000ZClinical outcomes of atrial tachyarrhythmia hospitalizations with and without prior thoracic irradiationhttps://www.pharmaradar360.com/article/case-report-persistent-indirect-hyperbilirubinemia-caused-by-gilbert-syndrome-mi-0745befaf019efc9Pharma Surgeen2026-07-16T00:00:00.000ZCase Report: Persistent indirect hyperbilirubinemia caused by Gilbert syndrome misdiagnosed as drug-induced liver injury during tuberculosis treatmenthttps://www.pharmaradar360.com/article/decoding-drug-resistance-and-apoptosis-in-biliary-tract-cancers-using-3d-tumor-m-f1882ff403485718Pharma Surgeen2026-07-16T00:00:00.000ZDecoding drug resistance and apoptosis in biliary tract cancers using 3D tumor modelshttps://www.pharmaradar360.com/article/association-of-early-supplemental-parenteral-nutrition-with-clinical-outcomes-in-b3fa44df63b054a1Pharma Surgeen2026-07-16T00:00:00.000ZAssociation of Early Supplemental Parenteral Nutrition with Clinical Outcomes in Patients with Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/clinical-characteristics-of-acute-chikungunya-cases-at-iahs-hospital-c7ed5940a10862efPharma Surgeen2026-07-16T00:00:00.000ZClinical Characteristics of Acute Chikungunya Cases at IAHS Hospitalhttps://www.pharmaradar360.com/article/bridging-periodontitis-and-clonal-hematopoiesis-implications-for-solid-tumor-met-e80b709b3ad681f0Pharma Surgeen2026-07-16T00:00:00.000ZBridging periodontitis and clonal hematopoiesis: implications for solid tumor metastasis, clinical trial design, and microbiome dynamics. Comment on: "Ligature-induced periodontitis promotes Dnmt3aR878H-driven clonal hematopoiesis"https://www.pharmaradar360.com/article/acne-care-online-protocol-for-a-randomised-trial-of-a-digital-behaviour-change-i-fac8e266a453cd0dPharma Surgeen2026-07-16T00:00:00.000ZAcne Care Online: protocol for a randomised trial of a digital behaviour change intervention to improve acne-related quality of life amongst 13-25 year oldshttps://www.pharmaradar360.com/article/predicting-the-risk-of-functional-impairment-in-older-adults-a-patient-centered-e2975fe00e0ddbe6Pharma Surgeen2026-07-16T00:00:00.000ZPREDICTING THE RISK OF FUNCTIONAL IMPAIRMENT IN OLDER ADULTS: A PATIENT-CENTERED APPROACH BASED ON THE WHO ICOPE INTRINSIC CAPACITY SCREENINGhttps://www.pharmaradar360.com/article/genetic-and-phenotypic-features-familial-intrahepatic-cholestasis-case-report-cdba1caa3ddcecf1Pharma Surgeen2026-07-16T00:00:00.000ZGenetic and phenotypic features familial intrahepatic cholestasis: case reporthttps://www.pharmaradar360.com/article/design-synthesis-and-biological-evaluation-of-novel-sulphur-containing-heterocyc-bc30da8c538bd1e1Pharma Surgeen2026-07-16T00:00:00.000ZDesign, Synthesis and Biological Evaluation of Novel Sulphur Containing Heterocycles as Potential Drug Candidateshttps://www.pharmaradar360.com/article/predictors-of-emergence-delirium-in-adults-receiving-sevoflurane-anaesthesia-emp-7a6e5fcdb5e2e092Pharma Surgeen2026-07-16T00:00:00.000ZPredictors of Emergence Delirium in Adults Receiving Sevoflurane Anaesthesia: Emphasis on Hypertension and Diabeteshttps://www.pharmaradar360.com/article/comparative-study-of-anti-parkinson-activity-of-mucuna-pruriens-extract-and-synt-44c8a7e52cef0ab9Pharma Surgeen2026-07-16T00:00:00.000ZComparative Study of Anti-Parkinson Activity of Mucuna pruriens Extract and Synthetic Levodopa Using HaloperidolInduced Catalepsy Modelhttps://www.pharmaradar360.com/article/artificial-intelligence-in-endodontic-decision-making-hallucinations-and-emergin-a126f217c7b53da7Pharma Surgeen2026-07-16T00:00:00.000ZArtificial intelligence in endodontic decision-making: hallucinations and emerging challenges for clinical practicehttps://www.pharmaradar360.com/article/efficacy-and-safety-of-postoperative-analgesia-for-intercostal-catheterization-g-455069bfd794a25ePharma Surgeen2026-07-16T00:00:00.000ZEfficacy and safety of postoperative analgesia for intercostal catheterization guided by thoracoscopy in single port thoracoscopic surgery: a prospective randomized controlled trialhttps://www.pharmaradar360.com/article/an-algorithmic-process-to-develop-clinical-practice-guideline-recommendations-ba-c8878972e9b95d4dPharma Surgeen2026-07-16T00:00:00.000ZAn algorithmic process to develop clinical practice guideline recommendations based on meta-analyses of the relevant evidencehttps://www.pharmaradar360.com/article/noninvasive-assessment-of-arterial-compliance-and-lumen-pressure-in-human-caroti-e052ef5de579ecfePharma Surgeen2026-07-16T00:00:00.000ZNoninvasive Assessment of Arterial Compliance and Lumen Pressure in Human Carotid Arteries Using Physics-Informed Neural Networks and Ultrasound Imaging: A Clinical Feasibility Studyhttps://www.pharmaradar360.com/article/iterative-feedback-refinement-for-faithful-structured-clinical-note-representati-f3267ca886e9a9adPharma Surgeen2026-07-16T00:00:00.000ZIterative Feedback--Refinement for Faithful Structured Clinical-Note Representationhttps://www.pharmaradar360.com/article/cement-compression-device-for-cemented-total-knee-arthroplasty-6931c96ea82a13f5Pharma Surgeen2026-07-16T00:00:00.000ZCement compression device for cemented total knee arthroplastyhttps://www.pharmaradar360.com/article/clinical-study-on-the-3d-morphology-and-mechanical-factors-of-lumbar-facet-joint-ed5ce2111a49a74cPharma Surgeen2026-07-16T00:00:00.000ZClinical study on the 3D morphology and mechanical factors of lumbar facet joints in patients with degenerative lumbar spondylolisthesishttps://www.pharmaradar360.com/article/idiopathic-mesenteric-phlebosclerosis-associated-with-long-term-herbal-medicine-39bf111eb76629a3Pharma Surgeen2026-07-16T00:00:00.000ZIdiopathic mesenteric phlebosclerosis associated with long-term herbal medicine use: A case reporthttps://www.pharmaradar360.com/article/eccentric-semilunar-penetrating-keratoplasty-for-peripheral-corneal-perforation-d40fd4517f4e80b9Pharma Surgeen2026-07-16T00:00:00.000ZEccentric semilunar penetrating keratoplasty for peripheral corneal perforation following chemical eye injury: A case reporthttps://www.pharmaradar360.com/article/long-term-survival-in-patients-with-primary-malignant-brain-tumors-after-postope-55fcb04504bef176Pharma Surgeen2026-07-16T00:00:00.000ZLong-term survival in patients with primary malignant brain tumors after postoperative home hydrogen inhalation: Three case reportshttps://www.pharmaradar360.com/article/clinical-and-electroencephalographic-characteristics-of-epilepsy-following-hypox-7b8674b64aec8401Pharma Surgeen2026-07-16T00:00:00.000ZClinical and electroencephalographic characteristics of epilepsy following hypoxic-ischemic encephalopathy: a retrospective analysishttps://www.pharmaradar360.com/article/comparative-effectiveness-of-mepolizumab-and-omalizumab-in-patients-eligible-for-943b90b436b13b82Pharma Surgeen2026-07-16T00:00:00.000ZComparative effectiveness of mepolizumab and omalizumab in patients eligible for both: a retrospective cohort studyhttps://www.pharmaradar360.com/article/twist1-bridges-p53-and-mdm2-and-impairs-the-efficacy-of-mdm2-inhibitors-69ccd431ee53bf3aPharma Surgeen2026-07-16T00:00:00.000ZTWIST1 bridges p53 and MDM2 and impairs the efficacy of MDM2 inhibitorshttps://www.pharmaradar360.com/article/correction-comparing-xenium-5k-and-visium-hd-data-from-identical-tissue-slide-at-392e2dd9091b59f0Pharma Surgeen2026-07-16T00:00:00.000ZCorrection: Comparing Xenium 5K and Visium HD data from identical tissue slide at a pathological perspectivehttps://www.pharmaradar360.com/article/i-ehrlichia-canis-i-seropositivity-in-a-hospital-based-dog-population-in-kars-tu-9ce6fb086e974bcaPharma Surgeen2026-07-16T00:00:00.000Z<i>Ehrlichia canis</i> Seropositivity in a Hospital-Based Dog Population in Kars (Türkiye): IFAT–ELISA Comparison and Associated Demographic, Clinical, and Hematological Findingshttps://www.pharmaradar360.com/article/itgbl1-myh9-interaction-in-hepatic-stellate-cells-acts-as-a-mechano-regulator-co-6c3adf53c86024b2Pharma Surgeen2026-07-16T00:00:00.000ZITGBL1-MYH9 interaction in hepatic stellate cells acts as a mechano-regulator controlling liver fibrosis in micehttps://www.pharmaradar360.com/article/comprehensive-evaluation-of-clinical-developmental-genetic-and-reproductive-char-b7b6e0a11308e98cPharma Surgeen2026-07-16T00:00:00.000ZComprehensive Evaluation of Clinical, Developmental, Genetic, and Reproductive Characteristics of 133 Patients with Klinefelter Syndromehttps://www.pharmaradar360.com/article/anal-cancer-screening-introduction-into-routine-clinical-care-for-key-population-580cdd05b7e6fcb3Pharma Surgeen2026-07-16T00:00:00.000ZAnal cancer screening: introduction into routine clinical care for key populationshttps://www.pharmaradar360.com/article/the-effect-of-preoperative-chewing-gum-on-anxiety-and-postoperative-sore-throat-dbbf65e8da646a18Pharma Surgeen2026-07-16T00:00:00.000ZThe Effect of Preoperative Chewing Gum on Anxiety and Postoperative Sore Throat in Patients Using a Laryngeal Mask Airway: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/how-ai-reshapes-clinical-knowledge-a-knowledge-lifecycle-model-of-ai-adoption-in-3e44d6681be750a7Pharma Surgeen2026-07-16T00:00:00.000ZHow AI reshapes clinical knowledge: a knowledge lifecycle model of AI adoption in hearing carehttps://www.pharmaradar360.com/article/ubiquitination-related-diagnostic-biomarkers-for-diabetic-nephropathy-insights-f-89220451cdb436bfPharma Surgeen2026-07-16T00:00:00.000ZUbiquitination‐Related Diagnostic Biomarkers for Diabetic Nephropathy: Insights From Multiomic Analysis, Drug Docking, and Experimental Validationhttps://www.pharmaradar360.com/article/clinical-features-of-clostridial-necrotizing-soft-tissue-infections-analysis-of-ff49f52ac24042f5Pharma Surgeen2026-07-16T00:00:00.000ZClinical Features of Clostridial Necrotizing Soft-Tissue Infections: Analysis of a Prospective Scandinavian Cohort Studyhttps://www.pharmaradar360.com/article/acquired-methemoglobinemia-from-intentional-exposure-to-uncommon-agrochemicals-a-19ec700b5c240c76Pharma Surgeen2026-07-16T00:00:00.000ZAcquired methemoglobinemia from intentional exposure to uncommon agrochemicals: a case serieshttps://www.pharmaradar360.com/article/an-in-vivo-study-on-extended-release-formulation-of-buprenorphine-in-sprague-daw-90644077fb0a8f2aPharma Surgeen2026-07-16T00:00:00.000ZAn in vivo study on extended-release formulation of buprenorphine in Sprague–Dawley ratshttps://www.pharmaradar360.com/article/correction-too-stressed-to-cope-a-multiple-mediation-analysis-of-social-bonds-sl-31d3d3acfc72e68ePharma Surgeen2026-07-16T00:00:00.000ZCorrection: Too stressed to cope? A multiple mediation analysis of social bonds, sleep quality, and sleep disturbances in relation to prescription drug use among Chinese high school seniorshttps://www.pharmaradar360.com/article/multifaceted-roles-of-isthmin-1-in-health-and-disease-mechanism-and-therapeutic-7d99eb4a14010fd3Pharma Surgeen2026-07-16T00:00:00.000ZMultifaceted roles of Isthmin-1 in health and disease: mechanism and therapeutic interventionhttps://www.pharmaradar360.com/article/early-vitrectomy-and-intravitreal-antibiotics-for-post-operative-exogenous-endop-e297fef48b7197efPharma Surgeen2026-07-16T00:00:00.000ZEarly vitrectomy and intravitreal antibiotics for post-operative exogenous endophthalmitis (EVIAN): a randomised control trial of feasibilityhttps://www.pharmaradar360.com/article/repurposing-the-antiplatelet-drug-prasugrel-for-parkinson-s-disease-evidence-of-ca5e5844d11b3d9fPharma Surgeen2026-07-16T00:00:00.000ZRepurposing the antiplatelet drug prasugrel for Parkinson’s disease: evidence of neuroprotective effects and proteomic profileshttps://www.pharmaradar360.com/article/asciminib-monotherapy-in-patients-with-bcr-abl1-t315i-mutated-chronic-phase-chro-b097b6e97f5a52faPharma Surgeen2026-07-16T00:00:00.000ZAsciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final resultshttps://www.pharmaradar360.com/article/team-science-training-needs-and-preferences-for-clinical-research-professionals-d55403403383a61bPharma Surgeen2026-07-16T00:00:00.000ZTeam Science Training Needs and Preferences for Clinical Research Professionalshttps://www.pharmaradar360.com/article/sudden-memory-loss-e49beb3fea03c44fPharma Surgeen2026-07-16T00:00:00.000ZSudden Memory Losshttps://www.pharmaradar360.com/article/incontinence-and-fatigue-ceb891240fba2e45Pharma Surgeen2026-07-16T00:00:00.000ZIncontinence and Fatiguehttps://www.pharmaradar360.com/article/progressive-imbalance-f6ce88b41111683cPharma Surgeen2026-07-16T00:00:00.000ZProgressive Imbalancehttps://www.pharmaradar360.com/article/progressive-fatigue-c01a23e3aff631e5Pharma Surgeen2026-07-16T00:00:00.000ZProgressive Fatiguehttps://www.pharmaradar360.com/article/the-association-between-psychodermatological-behaviors-economic-burden-and-perce-7c09821946326903Pharma Surgeen2026-07-16T00:00:00.000ZThe Association Between Psychodermatological Behaviors, Economic Burden, and Perception of Clinical Severity in Telogen Effluvium: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/histological-spectrum-and-determinants-of-survival-in-malignant-mesothelioma-mul-15328eafc223890dPharma Surgeen2026-07-16T00:00:00.000ZHistological Spectrum and Determinants of Survival in Malignant Mesothelioma: Multivariate Analysis from a Five-Year North Indian Tertiary Cancer Center Cohorthttps://www.pharmaradar360.com/article/efficacy-and-safety-of-brensocatib-in-participants-of-asian-race-with-non-cystic-91ea6c8b19a124a9Pharma Surgeen2026-07-16T00:00:00.000ZEfficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trialhttps://www.pharmaradar360.com/article/italian-association-of-nuclear-medicine-molecular-imaging-and-therapy-aimn-pract-d54aee8d696342c3Pharma Surgeen2026-07-16T00:00:00.000ZItalian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for lymphoscintigraphy and sentinel lymph node biopsy in melanomahttps://www.pharmaradar360.com/article/transitioning-therapeutic-antibodies-in-oncology-from-intravenous-to-hyaluronida-d9917444802a53c6Pharma Surgeen2026-07-16T00:00:00.000ZTransitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administrationhttps://www.pharmaradar360.com/article/stromal-and-tumoral-claudin-1-expression-in-odontogenic-tumors-correlation-with-bb765174210a4751Pharma Surgeen2026-07-16T00:00:00.000ZStromal and Tumoral Claudin-1 Expression in Odontogenic Tumors: Correlation with β-Catenin and Clinical Outcomeshttps://www.pharmaradar360.com/article/human-umbilical-cord-mesenchymal-stem-cells-in-metabolic-dysfunction-associated-c629ccb74ccad73ePharma Surgeen2026-07-16T00:00:00.000ZHuman Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectiveshttps://www.pharmaradar360.com/article/restless-legs-syndrome-and-mental-health-disturbances-clinical-implications-and-29b9f207c5cad399Pharma Surgeen2026-07-16T00:00:00.000ZRestless Legs Syndrome and Mental Health Disturbances: Clinical Implications and Current Treatment Optionshttps://www.pharmaradar360.com/article/ex-vivo-expanded-autologous-hematopoietic-stem-cells-stimulate-improved-immunoge-6ab80d6f3da115caPharma Surgeen2026-07-16T00:00:00.000ZEx vivo expanded autologous hematopoietic stem cells stimulate improved immunogenic activity: an in-vitro preliminary study for future clinical useshttps://www.pharmaradar360.com/article/clinical-impact-of-adjuvant-chemotherapy-and-regimen-selection-in-stage-iii-colo-5c6be7c0e02f2baaPharma Surgeen2026-07-16T00:00:00.000ZClinical impact of adjuvant chemotherapy and regimen selection in Stage III colorectal cancer with impaired performance status: a multicenter cohort studyhttps://www.pharmaradar360.com/article/peri-implant-crevicular-fluid-stress-related-biomarkers-and-psychometric-scores-e73c7d637ad1313cPharma Surgeen2026-07-16T00:00:00.000ZPeri-implant crevicular fluid stress-related biomarkers and psychometric scores in peri-implant health and diseasehttps://www.pharmaradar360.com/article/nishida-procedure-versus-single-horizontal-muscle-transposition-in-monocular-ele-635b6ff9174c13d3Pharma Surgeen2026-07-16T00:00:00.000ZNishida procedure versus single horizontal muscle transposition in monocular elevation deficiencyhttps://www.pharmaradar360.com/article/efficacy-and-eeg-ecg-mechanisms-of-tavns-combined-with-teas-for-negative-symptom-3baaae6174223a1fPharma Surgeen2026-07-16T00:00:00.000ZEfficacy and EEG-ECG mechanisms of taVNS combined with TEAS for negative symptoms of schizophrenia: a protocol for a 2 × 2 factorial randomized controlled trialhttps://www.pharmaradar360.com/article/omitting-catheterization-after-ureteroscopic-lithotripsy-a-prospective-multicent-8a5b579aecf985a1Pharma Surgeen2026-07-16T00:00:00.000ZOmitting catheterization after ureteroscopic lithotripsy: a prospective, multicenter, randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-assessment-of-breast-volume-updated-3d-imaging-demonstrates-good-agreem-f859c853908e9a6ePharma Surgeen2026-07-16T00:00:00.000ZClinical assessment of breast volume: updated 3D imaging demonstrates good agreement to MRI measurementshttps://www.pharmaradar360.com/article/gcfh-mda-graph-collaborative-filtering-with-hypergraph-augmentation-for-mirna-dr-857fe72ab15b0598Pharma Surgeen2026-07-16T00:00:00.000ZGCFH-MDA: Graph Collaborative Filtering with Hypergraph Augmentation for MiRNA-Drug Association Predictionhttps://www.pharmaradar360.com/article/psychiatric-effects-of-cannabidiol-cannabinol-and-tetrahydrocannabinol-a-narrati-e09833a8a3ffcbc9Pharma Surgeen2026-07-16T00:00:00.000ZPsychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profileshttps://www.pharmaradar360.com/article/congenital-sparse-and-brittle-hair-in-a-child-877abe3542d6efb3Pharma Surgeen2026-07-16T00:00:00.000ZCongenital Sparse and Brittle Hair in a Childhttps://www.pharmaradar360.com/article/nct07709572-effectiveness-of-acceptance-and-commitment-therapy-for-chronic-non-m-0240841f011cb1dePharma Surgeen2026-07-16T00:00:00.000ZNCT07709572: Effectiveness of Acceptance and Commitment Therapy for Chronic Non-Malignant Pain: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07709312-the-effect-of-ginkgo-biloba-on-rheumatoid-arthritis-patients-eee749566bb70e3ePharma Surgeen2026-07-16T00:00:00.000ZNCT07709312: the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patientshttps://www.pharmaradar360.com/article/nct07709286-clinical-efficacy-of-antivet-versus-phosphoric-acid-and-hydrochloric-2f03ac818a4f1c27Pharma Surgeen2026-07-16T00:00:00.000ZNCT07709286: Clinical Efficacy of Antivet Versus Phosphoric Acid and Hydrochloric Acid in Microabrasionhttps://www.pharmaradar360.com/article/nct07709208-mitral-valve-edge-to-edge-repair-in-patients-with-exercise-induced-s-d7dc66f874b3f931Pharma Surgeen2026-07-16T00:00:00.000ZNCT07709208: Mitral Valve Edge-to-Edge Repair in Patients With Exercise-Induced Severe Mitral Regurgitationhttps://www.pharmaradar360.com/article/nct07709156-conventional-high-intensity-laser-and-magnetic-field-therapies-in-ca-48a3155bd34cac88Pharma Surgeen2026-07-16T00:00:00.000ZNCT07709156: Conventional, High-Intensity Laser, and Magnetic Field Therapies in Carpal Tunnel Syndromehttps://www.pharmaradar360.com/article/nct07708961-temozolomide-with-or-without-wsd0922-fu-for-the-treatment-of-egfr-mu-9427f2ba36d40758Pharma Surgeen2026-07-16T00:00:00.000ZNCT07708961: Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastomahttps://www.pharmaradar360.com/article/nct07708753-a-study-of-sys6043-in-platinum-resistant-advanced-ovarian-primary-pe-202c951eb1ed6b22Pharma Surgeen2026-07-16T00:00:00.000ZNCT07708753: A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancershttps://www.pharmaradar360.com/article/nct07708636-upright-pro-prospective-development-study-of-upright-proton-therapy-a33488a935ffac54Pharma Surgeen2026-07-16T00:00:00.000ZNCT07708636: UPRIGHT-PRO: Prospective Development Study of Upright Proton Therapyhttps://www.pharmaradar360.com/article/nct07708623-clinical-trial-of-the-safety-and-tolerability-of-the-drug-mmh-450-in-b669da1083938777Pharma Surgeen2026-07-16T00:00:00.000ZNCT07708623: Clinical Trial of the Safety and Tolerability of the Drug MMH-450 in Healthy Volunteershttps://www.pharmaradar360.com/article/nct07708350-hematopoietic-stem-cell-bcl11a-enhancer-gene-editing-for-sickle-cell-96faa3d54e3ad78dPharma Surgeen2026-07-16T00:00:00.000ZNCT07708350: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Diseasehttps://www.pharmaradar360.com/article/nct07708220-laparoscopic-management-of-gastroesophageal-reflux-disease-in-childr-dc81441f06bf1a4cPharma Surgeen2026-07-16T00:00:00.000ZNCT07708220: Laparoscopic Management of Gastroesophageal Reflux Disease in Childrenhttps://www.pharmaradar360.com/article/nct07707856-ai-prediction-of-treatment-response-in-dme-d043ee9185968556Pharma Surgeen2026-07-16T00:00:00.000ZNCT07707856: AI Prediction of Treatment Response in DMEhttps://www.pharmaradar360.com/article/nct07707362-improving-care-delivery-for-patients-with-mental-illness-and-cancer-af1234d218b65412Pharma Surgeen2026-07-16T00:00:00.000ZNCT07707362: Improving Care Delivery for Patients With Mental Illness and Cancer Across a Cancer Center Networkhttps://www.pharmaradar360.com/article/nct07706842-ataraxis-real-world-clinical-outcomes-registry-linking-ai-based-path-49e2fd1534a897d0Pharma Surgeen2026-07-16T00:00:00.000ZNCT07706842: Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomeshttps://www.pharmaradar360.com/article/nct07706829-artificial-intelligence-based-parkinson-s-disease-risk-assessment-ai-8e2b16edfe4bc569Pharma Surgeen2026-07-16T00:00:00.000ZNCT07706829: Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Studyhttps://www.pharmaradar360.com/article/nct07702968-low-field-mri-in-stroke-code-patients-0231fdab4b921f3fPharma Surgeen2026-07-16T00:00:00.000ZNCT07702968: Low-Field MRI in Stroke Code Patientshttps://www.pharmaradar360.com/article/nct07678970-a-study-of-si-b036-in-patients-with-locally-advanced-or-metastatic-g-afaee15b84d8ca81Pharma Surgeen2026-07-16T00:00:00.000ZNCT07678970: A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumorshttps://www.pharmaradar360.com/article/nct07671092-imaging-study-in-metastatic-uc-hr-and-her2-breast-cancer-tnbc-and-ns-9403545c79946691Pharma Surgeen2026-07-16T00:00:00.000ZNCT07671092: Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLChttps://www.pharmaradar360.com/article/nct07662798-a-study-of-food-effect-on-tersolisib-ly4064809-in-healthy-participan-82179a6e2f2fd09aPharma Surgeen2026-07-16T00:00:00.000ZNCT07662798: A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participantshttps://www.pharmaradar360.com/article/nct07644559-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-pancre-4b8b576b31afa3a4Pharma Surgeen2026-07-16T00:00:00.000ZNCT07644559: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancerhttps://www.pharmaradar360.com/article/nct07640802-psychotherapy-for-irritability-in-youth-comparing-active-treatment-t-7d4264b318da1809Pharma Surgeen2026-07-16T00:00:00.000ZNCT07640802: Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapyhttps://www.pharmaradar360.com/article/nct07566494-escalating-doses-of-vas-101-in-subjects-with-stable-sickle-cell-dise-89e71199b72a100fPharma Surgeen2026-07-16T00:00:00.000ZNCT07566494: Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Diseasehttps://www.pharmaradar360.com/article/nct07543692-safety-and-effectiveness-of-ultrasound-guided-pharmacopuncture-for-s-7b83d90e1087c92bPharma Surgeen2026-07-16T00:00:00.000ZNCT07543692: Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseaseshttps://www.pharmaradar360.com/article/nct07497503-a-study-of-b-3e07-and-forsteo-in-healthy-adult-female-participants-996548958f92f81ePharma Surgeen2026-07-16T00:00:00.000ZNCT07497503: A Study of B-3E07 and Forsteo® in Healthy Adult Female Participantshttps://www.pharmaradar360.com/article/nct07404202-a-multicenter-non-interventional-descriptive-study-to-assess-assay-c-7194a63433bee2a5Pharma Surgeen2026-07-16T00:00:00.000ZNCT07404202: A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patientshttps://www.pharmaradar360.com/article/nct07271186-study-to-assess-the-effects-of-angiopoietin-like-protein-3-angptl3-i-959f79f0052f06ccPharma Surgeen2026-07-16T00:00:00.000ZNCT07271186: Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Diseasehttps://www.pharmaradar360.com/article/nct07224113-assessment-and-educational-intervention-to-reduce-ultra-processed-fo-03da67cc65f300f7Pharma Surgeen2026-07-16T00:00:00.000ZNCT07224113: Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBDhttps://www.pharmaradar360.com/article/nct07039539-harm-reduction-intervention-for-anabolic-androgenic-steroids-users-a-accb9a996110a3cbPharma Surgeen2026-07-16T00:00:00.000ZNCT07039539: Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07005297-clinical-genetics-branch-eligibility-screening-survey-e7dec4054d0f1b0fPharma Surgeen2026-07-16T00:00:00.000ZNCT07005297: Clinical Genetics Branch Eligibility Screening Surveyhttps://www.pharmaradar360.com/article/nct07005128-a-study-comparing-tarlatamab-durvalumab-carboplatin-and-etoposide-ve-a1d53e72636e27c2Pharma Surgeen2026-07-16T00:00:00.000ZNCT07005128: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)https://www.pharmaradar360.com/article/nct06912763-reversing-external-beam-radiotherapy-associated-fibrosis-syndrome-an-0754538735bc8fd0Pharma Surgeen2026-07-16T00:00:00.000ZNCT06912763: Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)